Today, clinicians are faced with the challenge of adequately treating a large number of patients with acute and chronic pain, while mitigating the risks associated with treatment. Our ability to manage pain, now competes against the crisis of opioid abuse and adverse outcomes such as addiction, unintentional overdose, and death, resulting from inappropriate prescribing, abuse, and misuse of opioids.

These complexities require clinicians to have a strong understanding of all options for pain management including non-pharmacologic and non-opioid options, as well as when to appropriately consider opioid agents when other non-opioid approaches have proven unsuccessful in alleviating pain and the benefits outweigh the risks.  

The SAFE Opioid Risk Evaluation and Mitigation Strategy (REMS) symposium is designed to fulfill on specific requirements put forth by the FDA Education Blueprint for HCPs Involved in the Treatment and Monitoring of Patients with Pain. Six evidence-based CME modules will address topics such as; the fundamentals of pain management, assessment of patients in pain, identifying and mitigating risk factors for abuse and addiction, and how to appropriately integrate opioid analgesics into a pain treatment plan individualized to the needs of the patient. 

Additional topics to be covered include, tools to manage patients on opioids analgesics in pain settings, including initiating therapy, titrating and discontinuing use, as well as strategies to counsel patients on safe use, disposal, and ways to identify and manage opioid use disorder or addiction.  

Complete the entire SAFE Opioid Prescribing activity to receive your training completion certificate!  

Learning Objectives

  • Identify risk factors for opioid-related aberrant behavior
  • Differentiate between tolerance, physical dependence and addiction
  • Evaluate and manage adverse effects of ER/LA-opioids
  • Differentiate strategies for monitoring patient adherence
  • Assess the differences in opioid metabolism and how these impact appropriate ER/LA prescribing
  • Identify how opioid-drug interactions influence ER/LA opioid prescribing

Faculty Disclosures

Charles E. Argoff, MD, FABPM

Speaker’s Bureau for Allergan, Inc., Amgen Inc., BioDelivery Sciences International, Inc., Daiichi Sankyo, Inc., and Depomed, Inc. Advisory Board member for Braeburn Pharmaceuticals, Inc., Depomed, Inc., Kaléo Pharma, Pfizer Inc., Quest Pharmaceuticals, Inc., and Teva Pharmaceuticals. Consultant for Nevro and Vertex Pharmaceuticals Incorporated. Contracted Research for Grünenthal GmbH and Vertex Pharmaceuticals Incorporated. Ownership Interest in Depomed, Inc. and Pfizer Inc, 

Katherine E. Galluzzi, DO, CMD, FACOFP

No financial relationships to disclose. 

Oscar A. de Leon-Casasola, MD

No financial relationships to disclose. 

Michael J. Brennan, MD

Speakers Bureau member for Collegium Pharmaceutical, Inc. Depomed, Inc., Daiichi Sankyo, Inc., Purdue Pharma L.P, and Teva Pharmaceuticals. Advisory Board member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc. Depomed, Inc., Daiichi Sankyo, Inc., and Purdue Pharma L.P. Ownership Interest in Cara Therapeutics. 

Jeffrey Gudin, MD

Speakers Bureau member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Purdue Pharma L.P., and Salix Pharmaceuticals Inc. Advisory Board member for Depomed, Inc. Consultant BioDelivery Sciences International, Inc., Nektar Therapeutics, Pernix Therapeutics, and Quest Diagnostics. 

Bill McCarberg, MD, FABPM

Speakers Bureau member for Collegium Pharmaceutical Inc. Advisory Board member for Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Pernix Therapeutics, and Pfizer Inc. Has ownership interests in BioSpecifics Technologies Corp., Collegium Pharmaceutical, Galena Biopharma and Johnson & Johnson. 

Steven Stanos, DO

Consultant for myMatrixx. Contracted Research for Grünenthal GmbH. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

pmiCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

pmiCME is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This program has been approved for 1.50 contact hours of continuing education, which includes 0.49 hour of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 3 out of the 4 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.

Commercial Supporter

REMS Program Companies

Education Partner

Miller Medical Communications, LLC

Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.